NCT Number: NCT02143037
CM Treatment for Alcohol Dependence Using New Technology
Contingency management (CM) is highly efficacious for reducing substance use, and recent data suggest that reinforcing attendance at treatment can significantly improve treatment outcomes. Importantly, CM interventions that reinforce attendance are more likely to be adopted clinically than those that reinforce abstinence. Having objective indicators of drinking outcomes, nevertheless, is critical for quantifying the benefits of attendance-based CM treatment in alcohol abusing populations. New technology is now available to gauge alcohol use in patients' natural environments. The Secure Continuous Remote Alcohol Monitor (SCRAMx®) continuously monitors alcohol consumption 24 hours a day. As such, it may be ideal for objective evaluation of alcohol consumption during treatment intervention studies, including those that involve CM.
In this study, 114 patients participating in community based outpatient treatment programs for alcohol use disorders will wear SCRAMx for a 12-week period. They will be randomized to standard care or standard care plus CM, with reinforcement contingent upon attendance at treatment. The investigators will assess treatment attendance and alcohol use via SCRAMx and self reports. The investigators expect that patients randomized to the CM intervention will remain in treatment longer and show reductions in both SCRAMx assessed and self reported drinking days relative to those randomized to standard care.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Regional Network of Programs, Inc., Bridgeport, Connecticut, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- age 18 years or older
- current diagnosis of alcohol use disorder
- able to pass an informed consent quiz
- agree to wear a SCRAMx monitor for 12 weeks
- have a standard, SCRAMx compatible phone line in their home or agree to attend the clinic at least every other week for data downloads
- agree to sign an off-campus property transfer form and return SCRAMx equipment in 12 weeks
Exclusion criteria
- serious, uncontrolled psychiatric illness
- in recovery from pathological gambling
- unstable address
- intend to participate in activities incompatible with SCRAMx in the next 3 months
- are wearing SCRAMx for legal purposes
Treatment and study plan
Usual Care
BehavioralPrimary outcomes
-
longest duration of actively attending treatment
Time frame: 3 months
patient attendance to treatment groups as verified by clinic records (number of days attended out of number of days expected to treatment)
Sponsors and collaborators
Lead sponsor
UConn Health
Other
Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Registry information
Important dates
- Study start
- 2013
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- May 20, 2014
- Registry last updated
- May 17, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dual Reinforcement Contingency Management for Alcohol Use Disorders
NCT04064463
Alcohol Use Disorder, Alcohol-Related Disorders
Hartford, Connecticut, United States
View Trial DetailsContingency Management for Alcohol Use Disorders
NCT02135237
Alcohol Use Disorder, Alcohol-Related Disorders
New Britain, Connecticut, United States
View Trial DetailsCM for Patients With ALD After Liver Transplant
NCT06304467
Alcohol Liver Disease, Alcohol Use Disorder
Los Angeles, California, United States
View Trial DetailsOxytocin to Enhance Integrated Treatment for AUD and PTSD
NCT04523922
Alcohol Use Disorder, Alcohol-Related Disorders
Charleston, South Carolina, United States
View Trial Details